For the quarter ending 2025-09-30, EYPT made $966,000 in revenue. -$59,645,000 in net income. Net profit margin of -6174.43%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenues | 966,000 | 5,333,000 | 24,453,000 | 10,378,666.667 |
| Cost of sales | 721,000 | 165,000 | 805,000 | 928,000 |
| Research and development | 47,754,000 | 55,498,000 | 58,574,000 | 34,461,333.333 |
| Sales and marketing | 26,000 | 35,000 | 35,000 | 35,666.667 |
| General and administrative | 14,490,000 | 11,862,000 | 13,876,000 | 13,129,333.333 |
| Total operating expenses | 62,991,000 | 67,560,000 | 73,290,000 | 47,281,750 |
| Loss from operations | -62,025,000 | -62,227,000 | -48,837,000 | -37,702,000 |
| Interest and other income, net | 2,293,000 | 2,894,000 | 3,642,000 | 3,772,000 |
| Interest expense | - | - | - | 3,500 |
| Total other income, net | 2,293,000 | 2,894,000 | 3,642,000 | 3,895,666.667 |
| Net loss before income taxes | -59,732,000 | -59,333,000 | - | -32,695,000 |
| Provision for income taxes | 0 | 93,000 | - | 22,500 |
| Net loss | -59,732,000 | -59,426,000 | -45,195,000 | -33,836,333.333 |
| Unrealized gain (loss) on available-for-sale securities | 87,000 | -91,000 | -105,000 | -71,666.667 |
| Comprehensive income (loss) | -59,645,000 | -59,517,000 | -45,300,000 | -33,908,000 |
| Net loss per share - basic | -0.85 | -0.85 | -0.65 | -0.593 |
| Net loss per share - diluted | -0.85 | -0.85 | -0.65 | -0.593 |
| Weighted average common shares outstanding - basic | 70,168 | 69,926 | 69,767,000 | -18,130,900.667 |
| Weighted average common shares outstanding - diluted | 70,168 | 69,926 | 69,767,000 | -18,130,900.667 |
EyePoint Pharmaceuticals, Inc. (EYPT)
EyePoint Pharmaceuticals, Inc. (EYPT)